Case Note & Summary
The dispute arose between Glaxo Group Limited and Shreya Life Sciences Pvt. Ltd. regarding the cancellation of Trade Mark Registration No. 5001470 for the mark 'LEFOXIN BIOX'. Glaxo, a UK-based pharmaceutical company, sought cancellation under Section 57 of the Trade Marks Act, 1999, claiming that the Impugned Mark was deceptively similar to its registered mark 'LANOXIN', which has been in use since 1956. Shreya, the registered proprietor of the Impugned Mark, contended that Glaxo was not a 'person aggrieved' and that the marks were not similar enough to cause confusion. The court analyzed whether Glaxo had a legitimate grievance and if the similarity between the marks could mislead consumers. It concluded that Glaxo's long-standing use of its mark and the phonetic and visual similarities between the two marks justified Glaxo's standing as a person aggrieved. The court emphasized that the likelihood of confusion must be assessed from the perspective of an average consumer and found that the addition of 'BIOX' did not sufficiently distinguish the Impugned Mark from Glaxo's mark. Consequently, the court ruled in favor of Glaxo, cancelling the registration of the Impugned Mark due to its deceptive similarity to the Glaxo Mark.
Headnote
A) Trade Marks - Person Aggrieved - Definition and Scope - Trade Marks Act, 1999, Section 57 - The court held that Glaxo, as the owner of an earlier registered mark, qualifies as a 'person aggrieved' under Section 57(2) of the TM Act, allowing it to seek rectification of the Impugned Registration. The court emphasized the need for a liberal interpretation of 'person aggrieved' to protect public interest (Paras 12-16). B) Trade Marks - Deceptive Similarity - Likelihood of Confusion - Trade Marks Act, 1999, Section 11(1) - The court found that the Impugned Mark 'LEFOXIN BIOX' is deceptively similar to Glaxo's mark 'LANOXIN', creating a likelihood of confusion among consumers, thus warranting cancellation of the registration (Paras 17-42).
Issue of Consideration
Whether Glaxo is a 'person aggrieved' and if the Impugned Mark is deceptively similar to the Glaxo Mark.
Final Decision
The court ruled in favor of Glaxo, cancelling the registration of the Impugned Mark 'LEFOXIN BIOX' due to its deceptive similarity to Glaxo's mark 'LANOXIN', thereby upholding Glaxo's rights as a person aggrieved under the Trade Marks Act, 1999.
Law Points
- Trade Mark Registration
- Cancellation
- Deceptive Similarity
- Person Aggrieved
- Public Interest
